SG11202011743SA - Fusion proteins comprising progranulin - Google Patents
Fusion proteins comprising progranulinInfo
- Publication number
- SG11202011743SA SG11202011743SA SG11202011743SA SG11202011743SA SG11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA SG 11202011743S A SG11202011743S A SG 11202011743SA
- Authority
- SG
- Singapore
- Prior art keywords
- progranulin
- fusion proteins
- fusion
- proteins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862686579P | 2018-06-18 | 2018-06-18 | |
| US201862746338P | 2018-10-16 | 2018-10-16 | |
| PCT/US2019/037695 WO2019246071A1 (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202011743SA true SG11202011743SA (en) | 2021-01-28 |
Family
ID=67138158
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202011743SA SG11202011743SA (en) | 2018-06-18 | 2019-06-18 | Fusion proteins comprising progranulin |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US20210284702A1 (es) |
| EP (1) | EP3807322A1 (es) |
| JP (1) | JP2021527656A (es) |
| KR (1) | KR20210027377A (es) |
| CN (1) | CN112424233A (es) |
| AU (1) | AU2019288212A1 (es) |
| BR (1) | BR112020025306A2 (es) |
| CA (1) | CA3101202A1 (es) |
| CL (1) | CL2020003255A1 (es) |
| EC (1) | ECSP20081591A (es) |
| IL (1) | IL279510A (es) |
| MX (1) | MX2020012518A (es) |
| PE (1) | PE20210323A1 (es) |
| PH (1) | PH12020552189A1 (es) |
| SG (1) | SG11202011743SA (es) |
| TW (1) | TW202016152A (es) |
| WO (1) | WO2019246071A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017012802A (es) | 2015-04-07 | 2018-04-11 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
| CA2986048C (en) * | 2015-05-29 | 2021-10-26 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a disruption in a c9orf72 locus |
| EP3583120B1 (en) | 2017-02-17 | 2022-10-05 | Denali Therapeutics Inc. | Engineered transferrin receptor binding polypeptides |
| WO2019070577A1 (en) | 2017-10-02 | 2019-04-11 | Denali Therapeutics Inc. | FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES |
| CN111372655A (zh) | 2018-07-13 | 2020-07-03 | 艾利妥 | 抗分拣蛋白抗体及其使用方法 |
| KR20210064199A (ko) * | 2018-08-16 | 2021-06-02 | 데날리 테라퓨틱스 인크. | 조작된 이중특이성 단백질 |
| CN114981297A (zh) | 2019-12-23 | 2022-08-30 | 戴纳立制药公司 | 颗粒蛋白前体变体 |
| CN115279790A (zh) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| US20210393787A1 (en) * | 2020-06-17 | 2021-12-23 | Bioasis Technologies, Inc. | Compositions and methods for treating frontotemporal dementia |
| EP4215607A1 (en) * | 2020-09-18 | 2023-07-26 | IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) | Ptpsigma-fc fusion protein and pharmaceutical composition comprising same |
| CN116916947A (zh) | 2020-10-14 | 2023-10-20 | 戴纳立制药公司 | 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法 |
| AU2021362487A1 (en) | 2020-10-14 | 2023-06-08 | Denali Therapeutics Inc. | Methods for treating and monitoring frontotemporal dementia |
| TW202340459A (zh) * | 2021-12-17 | 2023-10-16 | 美商戴納立製藥公司 | 包含α—Ｌ—艾杜糖醛酸酶之融合蛋白及其方法 |
| WO2023198661A1 (en) * | 2022-04-12 | 2023-10-19 | F. Hoffmann-La Roche Ag | Fusion proteins targeted to the central nervous system |
| WO2023224956A1 (en) * | 2022-05-16 | 2023-11-23 | Denali Therapeutics Inc. | Transferrin receptor-binding domains and proteins comprising the same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010022175A1 (en) * | 2008-08-19 | 2010-02-25 | Yale University | Identification of sortilin as a neuronal receptor for the frontotemporal dementia protein, progranulin |
| MX2017012802A (es) * | 2015-04-07 | 2018-04-11 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
| BR112017024610A2 (pt) * | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
| WO2018024162A1 (en) * | 2016-08-03 | 2018-02-08 | Sunshine Lake Pharma Co., Ltd. | Glp-1 fusion protein comprising mutated immunoglobulin fc portion |
| JP2020510418A (ja) | 2017-02-17 | 2020-04-09 | デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | トランスフェリン受容体トランスジェニックモデル |
| US10143187B2 (en) | 2017-02-17 | 2018-12-04 | Denali Therapeutics Inc. | Transferrin receptor transgenic models |
-
2019
- 2019-06-18 SG SG11202011743SA patent/SG11202011743SA/en unknown
- 2019-06-18 CN CN201980039158.0A patent/CN112424233A/zh active Pending
- 2019-06-18 WO PCT/US2019/037695 patent/WO2019246071A1/en unknown
- 2019-06-18 US US17/253,391 patent/US20210284702A1/en not_active Abandoned
- 2019-06-18 EP EP19735097.8A patent/EP3807322A1/en active Pending
- 2019-06-18 JP JP2020570444A patent/JP2021527656A/ja active Pending
- 2019-06-18 MX MX2020012518A patent/MX2020012518A/es unknown
- 2019-06-18 AU AU2019288212A patent/AU2019288212A1/en active Pending
- 2019-06-18 BR BR112020025306-5A patent/BR112020025306A2/pt unknown
- 2019-06-18 PE PE2020002083A patent/PE20210323A1/es unknown
- 2019-06-18 TW TW108121124A patent/TW202016152A/zh unknown
- 2019-06-18 KR KR1020217001552A patent/KR20210027377A/ko active Search and Examination
- 2019-06-18 CA CA3101202A patent/CA3101202A1/en active Pending
-
2020
- 2020-12-11 PH PH12020552189A patent/PH12020552189A1/en unknown
- 2020-12-16 IL IL279510A patent/IL279510A/en unknown
- 2020-12-16 EC ECSENADI202081591A patent/ECSP20081591A/es unknown
- 2020-12-16 CL CL2020003255A patent/CL2020003255A1/es unknown
-
2023
- 2023-04-12 US US18/299,458 patent/US20230406898A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PE20210323A1 (es) | 2021-02-18 |
| CN112424233A (zh) | 2021-02-26 |
| CL2020003255A1 (es) | 2021-05-28 |
| IL279510A (en) | 2021-01-31 |
| WO2019246071A1 (en) | 2019-12-26 |
| BR112020025306A2 (pt) | 2021-03-09 |
| EP3807322A1 (en) | 2021-04-21 |
| CA3101202A1 (en) | 2019-12-26 |
| US20230406898A1 (en) | 2023-12-21 |
| MX2020012518A (es) | 2021-02-16 |
| US20210284702A1 (en) | 2021-09-16 |
| TW202016152A (zh) | 2020-05-01 |
| KR20210027377A (ko) | 2021-03-10 |
| JP2021527656A (ja) | 2021-10-14 |
| ECSP20081591A (es) | 2021-01-29 |
| AU2019288212A1 (en) | 2020-12-03 |
| PH12020552189A1 (en) | 2021-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202011743SA (en) | Fusion proteins comprising progranulin | |
| IL281954A (en) | Heterodimeric chimeric proteins | |
| EP3880814A4 (en) | FUSION PROTEIN | |
| EP3743438A4 (en) | CYTOKI FUSION PROTEINS | |
| EP3287470A4 (en) | Novel recombinant bi-functional fusion protein and preparation and application therefor | |
| GB201509413D0 (en) | Fusion protein | |
| SG11202012004SA (en) | Rna-targeting fusion protein compositions and methods for use | |
| HK1246316A1 (zh) | 細胞因子融合蛋白 | |
| EP3757218A4 (en) | MERGER PROTEIN | |
| DK3737402T3 (en) | Modificeret protein | |
| SG11202101904UA (en) | Spd-1 variant - fc fusion proteins | |
| GB201504691D0 (en) | Fusion protein | |
| ZA202003845B (en) | Fusion proteins | |
| IL290660A (en) | Medical protein concentrates | |
| SG11202110400QA (en) | Fusion protein and use thereof | |
| IL273271A (en) | A fusion protein containing a residue of FGF-18 | |
| IL281088A (en) | FLT3L - based chimeric proteins | |
| IL281203A (en) | Pneumococcal fusion protein vaccines | |
| IL279057A (en) | Antimicrobial fusion proteins containing endolysin and their uses | |
| IL273626A (en) | Immunomodulatory fusion proteins | |
| SG11202104912SA (en) | Fusion protein and use thereof | |
| ZA202102533B (en) | Fusion protein | |
| HK1257937A1 (zh) | 融合蛋白 | |
| IL281132A (en) | Combination therapies that include PD-1-based chimeric proteins | |
| ZA202007491B (en) | Stable fusion protein formulation |